BRAF^V600E Mutation Analysis in Fine-Needle Aspiration Cytology of Fixed Slide Specimens in Patients with Papillary Thyroid Carcinoma.

Q2 Medicine Medical Journal of the Islamic Republic of Iran Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI:10.47176/mjiri.38.83

Sara Cheraghi, Maryam Honardoost, Fereshteh Abdolmaleki, Mohammad E Khamseh

{"title":"BRAFV600E Mutation Analysis in Fine-Needle Aspiration Cytology of Fixed Slide Specimens in Patients with Papillary Thyroid Carcinoma.","authors":"Sara Cheraghi, Maryam Honardoost, Fereshteh Abdolmaleki, Mohammad E Khamseh","doi":"10.47176/mjiri.38.83","DOIUrl":null,"url":null,"abstract":"Background: Papillary thyroid carcinoma is the most frequent type of thyroid cancer. The BRAFV600E mutation is associated with tumor progression. We explored the utility of the BRAF molecular testing on fine needle aspiration fixed specimens of patients with confirmed diagnoses of papillary thyroid carcinoma.Methods: Fixed thyroid cytology slide specimens of 19 patients with Bethesda II to VI reports were used to detect BRAFV600E mutation by pyrosequencing of extracted DNA.Results: BRAFV600E mutation was detected in 25% of the specimens with Bethesda category III and IV nodules and in 73% of the nodules with Bethesda category V and VI.Conclusion: BRAF mutation analysis can be performed on fixed fine needle aspiration cytology specimens. Although the frequency of the mutation is higher in specimens with higher Bethesda category scores, it could support clinical decision-making in thyroid nodules with intermediate Bethesda category scores.","PeriodicalId":18361,"journal":{"name":"Medical Journal of the Islamic Republic of Iran","volume":"38 ","pages":"83"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11644031/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of the Islamic Republic of Iran","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47176/mjiri.38.83","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Papillary thyroid carcinoma is the most frequent type of thyroid cancer. The BRAF^V600E mutation is associated with tumor progression. We explored the utility of the BRAF molecular testing on fine needle aspiration fixed specimens of patients with confirmed diagnoses of papillary thyroid carcinoma.

Methods: Fixed thyroid cytology slide specimens of 19 patients with Bethesda II to VI reports were used to detect BRAF^V600E mutation by pyrosequencing of extracted DNA.

Results: BRAF^V600E mutation was detected in 25% of the specimens with Bethesda category III and IV nodules and in 73% of the nodules with Bethesda category V and VI.

Conclusion: BRAF mutation analysis can be performed on fixed fine needle aspiration cytology specimens. Although the frequency of the mutation is higher in specimens with higher Bethesda category scores, it could support clinical decision-making in thyroid nodules with intermediate Bethesda category scores.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

甲状腺乳头状癌患者固定切片标本细针抽吸细胞学中的 BRAFV600E 基因突变分析

背景：甲状腺乳头状癌是最常见的甲状腺癌类型。BRAFV600E突变与肿瘤进展有关。我们探讨BRAF分子检测在确诊为甲状腺乳头状癌患者的细针穿刺固定标本中的应用。方法：采用19例Bethesda II至VI报告患者的固定甲状腺细胞学切片标本，对提取的DNA进行焦磷酸测序检测BRAFV600E突变。结果：25%的Bethesda III类和IV类结节和73%的Bethesda V类和vi类结节中检测到BRAFV600E突变。结论：BRAFV600E突变分析可以在固定细针穿刺细胞学标本中进行。虽然在Bethesda分类评分较高的标本中突变的频率较高，但它可以为中等Bethesda分类评分的甲状腺结节的临床决策提供支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊